Zai Lab (ZLAB) Competitors

Zai Lab (NASDAQ:ZLAB) and Genmab A/S (NASDAQ:GMAB) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, dividends, valuation, institutional ownership, media sentiment and earnings.

Is ZLAB or GMAB more profitable?

Genmab A/S has a net margin of 35.11% compared to Zai Lab's net margin of -60.26%. Genmab A/S's return on equity of 18.08% beat Zai Lab's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zai Lab	-60.26%	-33.35%	-23.28%
Genmab A/S	35.11%	18.08%	14.52%

Which has higher earnings and valuation, ZLAB or GMAB?

Genmab A/S has higher revenue and earnings than Zai Lab. Zai Lab is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zai Lab	$418.33M	10.24	-$257.10M	-$2.49	-15.49
Genmab A/S	$3.12B	4.58	$1.14B	$1.76	12.65

Does the media refer more to ZLAB or GMAB?

In the previous week, Zai Lab had 1 more articles in the media than Genmab A/S. MarketBeat recorded 8 mentions for Zai Lab and 7 mentions for Genmab A/S. Genmab A/S's average media sentiment score of 1.14 beat Zai Lab's score of 0.92 indicating that Genmab A/S is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zai Lab	3 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
Genmab A/S	2 Very Positive mention(s)	3 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has more volatility & risk, ZLAB or GMAB?

Zai Lab has a beta of 0.99, suggesting that its share price is 1% less volatile than the S&P 500. Comparatively, Genmab A/S has a beta of 0.94, suggesting that its share price is 6% less volatile than the S&P 500.

Do analysts rate ZLAB or GMAB?

Zai Lab presently has a consensus price target of $54.28, suggesting a potential upside of 40.72%. Genmab A/S has a consensus price target of $37.80, suggesting a potential upside of 69.74%. Given Genmab A/S's higher possible upside, analysts plainly believe Genmab A/S is more favorable than Zai Lab.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zai Lab	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.80
Genmab A/S	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.64

Do insiders and institutionals hold more shares of ZLAB or GMAB?

41.7% of Zai Lab shares are owned by institutional investors. Comparatively, 7.1% of Genmab A/S shares are owned by institutional investors. 5.0% of Zai Lab shares are owned by company insiders. Comparatively, 1.5% of Genmab A/S shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Genmab A/S beats Zai Lab on 11 of the 17 factors compared between the two stocks.